重组人脑利钠肽对急性心力衰竭患者心功能和炎症介质的影响

Influence of rhBNP on cardiac function and modiator of inflammation in patients with acute heart failure

目的:评价重组人脑利钠肽(rhBNP)治疗急性心力衰竭(AHF)患者对心功能及炎症因子的影响。方法:90例AHF患者被随机分为常规治疗组(45例)及rhBNP组(45例,在常规治疗基础上静脉注射rhBNP,共3d)。比较两组治疗前后左室射血分数(LVEF),炎症介质:血清高敏C反应蛋白(hsCRP)、白细胞介素-6(IL-6)等水平的变化。结果:治疗后与常规治疗组比较,rhBNP组LVEF[(42.7±13.1)%比(50.9±14.5)%]显著提高,心率[(85.7±17.7)次/min比(73.5±16.1)次/min]、脑利钠肽[(1142.6±287.5)ng/L比(976.7±235.7)ng/L]、hsCRP[(8.45±2.68)mg/L比(6.82±2.57)mg/L]、IL-6[(16.07±4.75)pg/L比(13.35±4.18)pg/L]水平显著降低(P均<0.05)。结论:重组人脑利钠肽治疗急性心力衰竭效果显著,可改善患者预后。

Objective： To evaluate clinical therapeutic effects of recombinant human brain natriuretic peptide （rhB-NP, Xinhuosu） on cardiac function and modiator of inflammation in patients with acute heart failure （AHF）. Meth-ods： A total of 90 AHF patients were randomly divided into routine treatment group （n = 45） and rhBNP group （n = 45, received intravenous injection of rhBNP for 3d based on routine treatment）. Levels of LVEF and mediator of inflammation： serum hsCRP, interleukin-6 （IL- 6） were compared between two groups before and after treat-ment. Results： Compared with routine treatment group after treatment, there was significant increase in LVEF [ （42.7± 13.1） % vs. （50.9 ± 14.5） %], significant decrease in heart rate [ （85.7 ± 17.7） times/min vs. （73.5 ±16.1） times/mini, levels of brain natriuretic peptide [BNP, hsCRPE （8.45±2.68） mg/Lvs. （6.82±2.57） mg/L] andlL （1142.6± 287.5） ng/L vs. （976.7 ± 235.7） ng/L], -6[ （16.07±4.75） pg/Lvs. （13.35±4.18） pg/L] in rhBNP group, P〈0.05 all. Conclusion.. The rhBNP possesses significant effect on cardiac function and mediator of inflammation in AHF patients.